Brain-wave training for nerve pain caused by diabetes
Tests EEG neurofeedback against a sham version in adults with painful diabetic neuropathy.
Key facts
- Who runs it
- University of Southern Denmark
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Neurofeedback for the Management of Neuropathic Pain in People With Diabetes
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Sept 2024
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- EEG-neurofeedback
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes who have long-lasting nerve pain from diabetic nerve damage. It tests brain-wave training (EEG-neurofeedback) against a fake version.
- Age
- 18 to 82 years
- Sex
- All sexes
- Disease stage
- Type 1 diabetes for at least 5 years, or type 2 diabetes. At least probable diabetic nerve damage and probable nerve pain. Pain of at least 4 on a 0-10 scale for at least 3 months, on at least half of days. No other severe pain.
- Earlier treatment
- Pain medicine must have been stable for > 1 month before joining. It must not change during the trial (paracetamol is allowed as rescue medicine).
- Biomarker or test result
- At least one abnormal nerve test, for example TCNS > 5, DPNCheck amplitude < 4µV and/or conduction velocity < 40 m/s, or an abnormal nerve conduction study (NCS).
Main reasons for not taking part
- Other brain or nerve illness (such as epilepsy, migraine, stroke, tumor) or a significant mental illness
- Nerve damage or nerve pain from causes other than diabetes
- Heavy alcohol use (>14 units/week for women, >21 for men) or illegal drug abuse
- Pregnancy, or morphine use >20mg/day
- Blindness or severely impaired vision
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥18 and ≤82 years
- Diagnosed with 1) type 1 diabetes (for at least 5 years) or 2) type 2 diabetes
- Confirmed diagnosis of at least "Probable Diabetic Polyneuropathy" as defined by Toronto Consensus Criteria (Presence of a combination of symptoms and signs of neuropathy including any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes), and at least one of the following:; TCNS > 5; Abnormal DPNCheck results (amplitude < 4µV and/or conduction velocity < 40 m/s); Abnormal NCS (Nerve Conduction Study)
- Confirmed diagnosis of at least "Probable Neuropathic Pain" as defined by NeuPSIG guidelines (Pain distribution which makes neuropathic pain neuroanatomically plausible and history suggests relevant disease (e.g., symmetric pain in the feet/lower extremities and history of diabetes), and at least one of the following:; Negative or positive sensory signs, confined to innervation territory of the lesioned nervous structure (abnormal findings in at least one of: pinprick, temperature sensation, light touch (monofilament), vibration sense (biothesiometry or 128Hz tuning fork, position sense); Abnormal DPNCheck results (amplitude < 4µV and/or conduction velocity < 40 m/s); Abnormal NCS (Nerve Conduction Study)
- Eligible patients with painful DPN must have a pain intensity of at least 4 on an 11-point numerical rating scale (NRS, 0-10) for at least 3 months on at least semi-daily basis and no severe pain other than pain due to neuropathy (the pain intensity will be based on the pain the patients experience while on current pain treatment, if any)
- Stable pain medication for > 1 month prior to inclusion. Exclusion criteria
- Concomitant neurological (neurodegenerative disorders, migraine, epilepsy, stroke, tumor) or clinically significant psychiatric illness
- Neuropathy or neuropathic pain due to other causes than diabetes (vitamin B12 deficiency, prior treatment with neurotoxic chemotherapy, chronic alcohol abuse, spinal stenosis, etc.)
- Change in current pain treatment during treatment (paracetamol is allowed as rescue medicine)
- Prior or current excessive alcohol use (>14 or >21 units/week for women and men, respectively) or illegal substance abuse
- Positive urine hCG test result indicating pregnancy
- Morphine use >20mg/day
- Blindness or severely impaired vision
- The investigator finds the patient unfit for the study (e.g. due to use of alcohol or drugs, mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation or presence of any condition that in the investigators' opinion may lead to poor adherence to study protocol)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 82 years old?
This trial is currently available in Denmark.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
We will conduct a high-quality, blinded, randomized controlled trial (RCT) to rigorously test the effectiveness of EEG-based NF in patients with diabetes-related neuropathic pain. This study aims to determine the short-term and long-term effects of EEG-based NF on self-reported pain intensity, neuropathic pain symptoms, daily functioning, QoL and neurophysiological activity in individuals with chronic P-DPN. The trial is designed as a superiority trial. The primary aim is to evaluate whether real EEG-NF compared with sham EEG-NF, leads to a greater reduction in self-reported pain intensity from T0 to T1, assessed using mean 7-day pain intensity derived from the electronic pain diary. Secondary aims are to examine whether EEG-NF improves neuropathic pain severity, pain interference, sleep, fatigue, mood and QoL, and promotes normalization of activity within predefined pain-related cortical networks assessed using z-score changes in standardized weighted low-resolution electromagnetic tomography (swLORETA)-derived regions.
The 2 groups in the trial
- Real EEG-neurofeedbackTreatment being tested
the NF intervention group will receive feedback based on the genuine real-time EEG activity
Treatment: EEG-neurofeedback
- Sham EEG-neurofeedbackSham treatment, for comparison
The sham-group will receive another participant's EEG-training protocol as a prerecorded signal. The feedback signal will consist of 15-25 rewards per minute. Meanwhile, the threshold for the sham group remains fixed, ensuring a consistent 70% positive feedback rate.
Treatment: EEG-neurofeedback
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neurofeedback for the Management of Neuropathic Pain in People With Diabetes
- Plain-language title
- Brain-wave training for nerve pain caused by diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06603792, who can take part
- Record updated
- 15 September 2026